Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Adapting the PERCEPT myeloma prehabilitation trial to virtual delivery during the COVID-19 pandemic

Orla McCourt • 26 Aug 2022
IMS 2022
Multiple Myeloma

Orla McCourt, MSc, MCSP, University College London NHS Foundation Trust, London, UK, discusses the impact of the COVID-19 pandemic on the delivery of the PERCEPT myeloma prehabilitation trial, outlining the changes that were implemented to deliver the trial remotely, including substituting assessment measures and incorporating new measures to ensure participant safety. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Orla McCourt

3:54
Impact of pysiotherapist-led exercise prehabilitation before and during autoHSCT in multiple myeloma
Orla McCourt • 26 Aug 2022
2:31
The feasibility of physiotherapist-led exercise prehabilitation in patients with MM undergoing SCT
Orla McCourt • 26 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals